| Literature DB >> 32531996 |
Aleksandra Kaczorowska1, Weronika Lamperska2, Kaja Frączkowska1, Jan Masajada2, Sławomir Drobczyński2, Marta Sobas3, Tomasz Wróbel3, Kinga Chybicka4, Radosław Tarkowski5, Sebastian Kraszewski1, Halina Podbielska1, Wojciech Kałas4, Marta Kopaczyńska1.
Abstract
In our study, we describe the outcomes of the intercalation of different anthracycline antibiotics in double-stranded DNA at the nanoscale and single molecule level. Atomic force microscopy analysis revealed that intercalation results in significant elongation and thinning of dsDNA molecules. Additionally, using optical tweezers, we have shown that intercalation decreases the stiffness of DNA molecules, that results in greater susceptibility of dsDNA to break. Using DNA molecules with different GC/AT ratios, we checked whether anthracycline antibiotics show preference for GC-rich or AT-rich DNA fragments. We found that elongation, decrease in height and decrease in stiffness of dsDNA molecules was highest in GC-rich dsDNA, suggesting the preference of anthracycline antibiotics for GC pairs and GC-rich regions of DNA. This is important because such regions of genomes are enriched in DNA regulatory elements. By using three different anthracycline antibiotics, namely doxorubicin (DOX), epirubicin (EPI) and daunorubicin (DAU), we could compare their detrimental effects on DNA. Despite their analogical structure, anthracyclines differ in their effects on DNA molecules and GC-rich region preference. DOX had the strongest overall effect on the DNA topology, causing the largest elongation and decrease in height. On the other hand, EPI has the lowest preference for GC-rich dsDNA. Moreover, we demonstrated that the nanoscale perturbations in dsDNA topology are reflected by changes in the microscale properties of the cell, as even short exposition to doxorubicin resulted in an increase in nuclei stiffness, which can be due to aberration of the chromatin organization, upon intercalation of doxorubicin molecules.Entities:
Keywords: DNA stiffness; DNA structural changes; cell nuclei stiffness; optical tweezers
Year: 2020 PMID: 32531996 PMCID: PMC7312087 DOI: 10.3390/ijms21114142
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Atomic force microscopy (AFM) and molecular dynamics images of DNA be fore and after the interaction with anthracyclines in the concentration of 2 µM. For DNA 35% GC AFM images are shown in figures (a1.1–a4.1) and molecular dynamics images are shown in figures (a1.2–a4.2) For DNA 52% GC AFM images are shown in figures (b1.1–b4.1) and molecular dynamics images are shown in figures (b1.2–b4.2). For DNA 77% GC AFM images are shown in figures (c1.1–c4.1) and molecular dynamics images are shown in figures (c1.2–c4.2).
Figure 2Correlation of dsDNA length and height changes depending on the anthracycline (a,d—doxorubicin (DOX); b,e—daunorubicin (DAU); c,f—epirubicin (EPI)) type and concentration (a,b,c—0.3 µM; d,e,f—2 µM). The raw data are included in Table S1 and Table S2.
Figure 3The scheme of the stretching process of (a) DNA chain and (b) cell nucleus. Two microbeads are trapped in two separate optical traps and are connected with each other by the DNA or cell nucleus. One bead (left) is immobile, whereas the second bead (right) is slowly pulled away from the first one.
Figure 4An exemplary record of the stretching experiment in a quasi-static manner. In the first stage, the DNA chain gets untangled and straightened to its actual length, dictated by the number of base pairs in the chain. This corresponds to the flat part of the curve (step 1 and 2). Next, the actual stretching and lengthening of the DNA chain occurs (step 3 and step 4) followed by the DNA breakage (step 5). The slope of the fitted linear function (red) is a direct measure of the chain stiffness. The whole process takes about 20–30 s.
DNA stiffness and breakage force. Doxorubicin (DOX), daunorubicin (DAU) and epirubicin (EPI) concentrations were 12 µM.
| DNA Stiffness [pN/µm] | |||
|---|---|---|---|
| Sample | AT-Rich | Balanced | GC-Rich |
| Untreated | 24 ± 5 | 21 ± 4 | 22 ± 5 |
| DOX | 18 ± 5 | 14 ± 3 | 8 ± 3 |
| DAU | 12 ± 1 | 19 ± 3 | 11 ± 4 |
| EPI | 12 ± 1 | 15 ± 4 | 10 ± 3 |
|
| |||
|
|
|
|
|
| Untreated | - | 8.0 ± 1.5 | 12.6 ± 1.5 |
| DOX | - | 11.0 ± 2.5 | 9.0 ± 1.8 |
| DAU | - | 9.0 ± 1.5 | 9.6 ± 1.5 |
| EPI | 8.5 ± 4.5 | 11.0 ± 0.5 | 9.3 ± 1.8 |
Figure 5Daunorubicin affects the stiffness of isolated nuclei and the size of the nucleus of AML cells. (a) Nuclei stiffness, mean +/− standard deviations of the isolated nuclei are shown on the graph (n = 15), (b) area of nuclei of AML cells stained with PureBlu Hoechst 33342, average +/− standard deviations are shown on the graph (n = 40), asterisk indicates statistically significant difference (p < 0.01).